GSK has secured the first regulatory approval for Blenrep since the antibody-drug conjugate’s global market withdrawal in 2022. The U.K.’s Medicines and Healthcare products Regulatory Agency ...

At its 52-week peak on 16 May 2024, the GSK share price hit 1,823.5p, but it’s been mostly downhill ever since. Last week, as stock markets crashed, GSK shares collapsed to 1,242.5p on Wednesday 9 ...

GSK GSK and Pfizer PFE announced that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has recommended the expanded use of their ...

Some Delaware Supreme Court justices signaled they may be skeptical of a bid by GSK Plc, Pfizer Inc. and other drugmakers to overturn a judge who allowed more than 80,000 lawsuits to proceed to ...

The reversal from the Advisory Committee on Immunization Practices (ACIP) is a potential boost for GSK and Pfizer. Both companies saw sales of their RSV vaccines for adults tumble last year after ...

(Alliance News) - GSK PLC on Thursday said it has received authorisation from the UK Medicines & Healthcare products Regulatory Agency for Blenrep combinations in the treatment of adults with ...

(Reuters) -British pharmaceutical giant GSK has not met required ethical and regulatory standards in the marketing and prescription information for its Omjjara drug, an industry self-regulatory body ...

GSK said two of its vaccines obtained a positive recommendation from a U.S. body, aiming at tackling meningitis and the respiratory syncytial virus. The pharmaceutical company said Thursday that ...

The recommendation also includes GSK plc’s GSK Arexvy in adults aged 50-59 who are at increased risk for severe RSV disease. This expands on ACIP’s previous vote in June 2024 to recommend RSV ...